Literature DB >> 16843447

Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model.

Takuya Sasaki1, Feng Han, Norifumi Shioda, Shigeki Moriguchi, Jiro Kasahara, Koichi Ishiguro, Kohji Fukunaga.   

Abstract

Lithium used in bipolar mood disorder therapy protects neurons from brain ischemic cell death. Here, we documented that lithium administration under microsphere-embolism (ME)-induced brain ischemia restored decreased protein kinase B (Akt) and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) activities 24 h after ischemia in rat brain. Akt activation was associated with increased phosphorylation of its potential targets forkhead transcription factor (FKHR) and glycogen synthase kinase-3beta (GSK-3beta). In parallel with decreased CaMKII autophosphorylation, we also found marked dephosphorylation of tau proteins 24-72 h after ME. Increased protein phosphatase 2A (PP2A) activity was found 24 h after ME. Inhibition of increased PP2A activity by lithium treatment apparently mediated restored tau phosphorylation. Taken together, activation of Akt and CaMKII by lithium was associated with neuroprotective activity in ME-induced neuronal injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16843447     DOI: 10.1016/j.brainres.2006.06.009

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  26 in total

1.  Volatile anesthetic post-treatment induces protection via inhibition of glycogen synthase kinase 3β in human neuron-like cells.

Authors:  D Lin; G Li; Z Zuo
Journal:  Neuroscience       Date:  2011-01-28       Impact factor: 3.590

2.  Lithium treatment reduces brain injury induced by focal ischemia with partial reperfusion and the protective mechanisms dispute the importance of akt activity.

Authors:  Tetsuya Takahashi; Gary K Steinberg; Heng Zhao
Journal:  Aging Dis       Date:  2012-02-08       Impact factor: 6.745

3.  Long-term exposure to low lithium concentrations stimulates proliferation, modifies stress protein expression pattern and enhances resistance to oxidative stress in SH-SY5Y cells.

Authors:  M S Allagui; R Nciri; M F Rouhaud; J C Murat; A El Feki; F Croute; C Vincent
Journal:  Neurochem Res       Date:  2008-08-08       Impact factor: 3.996

4.  Ethanol causes and lithium prevents neuroapoptosis and suppression of pERK in the infant mouse brain.

Authors:  Chainllie Young; Megan M W Straiko; Stephen A Johnson; Catherine Creeley; John W Olney
Journal:  Neurobiol Dis       Date:  2008-07-02       Impact factor: 5.996

Review 5.  Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.

Authors:  O V Forlenza; V J R De-Paula; B S O Diniz
Journal:  ACS Chem Neurosci       Date:  2014-05-06       Impact factor: 4.418

6.  Lithium protects against anesthesia-induced developmental neuroapoptosis.

Authors:  Megan M W Straiko; Chainllie Young; Davide Cattano; Catherine E Creeley; Haihui Wang; Derek J Smith; Stephen A Johnson; Erin S Li; John W Olney
Journal:  Anesthesiology       Date:  2009-04       Impact factor: 7.892

7.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

Review 8.  The neurotrophic and neuroprotective effects of psychotropic agents.

Authors:  Joshua Hunsberger; Daniel R Austin; Ioline D Henter; Guang Chen
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

9.  Lithium-mediated protection against ethanol neurotoxicity.

Authors:  Jia Luo
Journal:  Front Neurosci       Date:  2010-06-28       Impact factor: 4.677

10.  Resveratrol inhibits neuronal apoptosis and elevated Ca2+/calmodulin-dependent protein kinase II activity in diabetic mouse retina.

Authors:  Young-Hee Kim; Yoon-Sook Kim; Sang-Soo Kang; Gyeong-Jae Cho; Wan-Sung Choi
Journal:  Diabetes       Date:  2010-04-27       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.